Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy

뉴스 본문을 불러오고 있어요.

Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy | 웨이프 WAPE

Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy

기사 요약

관련 종목

댓글 —